• NPPA'S HELPLINE NO. 1800111255 ( All Working Days ,10am to 6pm )

Glaxo Smithkline Pharma Ltd.

F.NO. 8 (42)/2002/DP/NPPA-Div.II




In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Price Control) Order, 1995, read with No. S.O. 637(E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority hereby fixes/revises the prices as specified in column (7) of the Table hereto annexed as the retail price/revised retail price, exclusive of local tax if any, in relation to each of the formulations specified in the corresponding entry in column (2) of the said Table with pack size specified in the corresponding entries in column (3) thereof;


Sl. No. Name of the Formulation Pack Size Existing Retail Price (Rs.) Retail Price without Excise Duty Excise Duty (Rs.) Revised Retail Price with Excise Duty (Rs.)
1 Grisovin FP Tablet 250mg
Each tab contains
10’s Al_Bl 18.18 23.38 2.89 26.27


  1. This order shall be applicable if the manufacturer of the formulation specified in column (2) of the Table above has complied with the requirements, if any, of

(a)         the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder; and

(b)         the Industries (Development and Regulation) Act, 1951 (65 of 1951) as amended from time to time.

3.(a)     The prices fixed/revised are the maximum retail prices (inclusive of excise duty and exclusive of local taxes, if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b)        For different packing material used or any special feature claimed, companies are required to approach NPPA for approval/fixation of specific prices.

  1. The Prices given in column 7 of the above table will remain valid subject to the condition that the company capatively consumes the bulk drug Griseofulvin produced by them and the company is required to submit the quarterly return duly certified by chartered accountant/cost accountant in prescribed proforma ensuring that company is using only its own manufactured bulk drug Griseofulvin in the above formulation pack.
  2. The ceiling price notified vide S.O. 786(E) dated 16.8.2001 for the above composition will not be applicable in this case.
  3. These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.

Dy. Director

M/s Glaxo Smithkline Pharma Ltd.
Dr. Annie Besant Road,
Mumbai-400 025

Last Page Updated: 31-05-2019